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Chronic administration of aL-isoproterenoi, a ~-adrenergic agonist, to male Sprague-Dawley rats increased 
submandibular gland weights by 3 to 4-fold. This increase resulted from a combination of hyperplasia and 
hypertrophy of secretory cells. Possible effects of this drug regimen on submandibular gland muscarinic 
acetylcholine receptors were examined by analysis of the binding of the cholinergic antagonist, L-quinuc- 
iidinyl [3H]benzilate, to receptors in gland homogenates. Parallel investigations of receptors in exorbital 
lacrimal glands, an organ that is not grossly affected by chronic isoproterenoi treatment, were also carried 
out. [3H]QNB bound to submandibular receptors with a K d of 37.8---+6.3 pM in control rats and 41.0-+4.0 
pM in isoproterenoi-treated animals, a non-significant difference (P  >0.05). In contrast, the maximal 
binding level (Bma x ) in isoproterenoi-treated rats, 1.52-+ 0.10 fmol//t g DNA, was depressed by approx. 30% 
(P  <0.05) from that of 2.22-+0.16 fmoi//zg DNA in control animals. In lacrimal glands, both K d (61.3-+5.3 
vs. 53.2-+4.0 pM) and Bma x (1.74-+0.24 vs. 1.78---0.17 fmol//tg DNA) were unchanged by isoproterenoi 
treatment. The affinity of glandular muscarinic receptors for cholinergic agonists was also examined by 
competition experiments using carbachol. This agonist inhibited [3H]QNB binding to receptors in homo- 
genates from both glands in a dose-dependent fashion. Inhibition constants (Ki) for this interaction were 
similar in control and isoproterenol-treated lacrimal glands; 53.6-+ 5.4/t M and 66.6-+ 7.9/t M, respectively 
(P  >0.05). In submandibular glands, isoproterenol treatment elicited a highly significant (P <0.01) shift in 
K i from 17.3-+1.4 / tM to 68.3-+5.2 pM. These results demonstrate that chronic administration of 
isoproterenoi to rats results in a reduction in receptor numbers and a decrease in their sensitivity to 
cholinergic agonists in submandibular, but not lacrimal, glands. 
Introduction 
Chronic administration of the fl-adrenergic 
agonist, DL-isoproterenol, to rodents causes a pro- 
found enlargement of the parotid and submandib- 
ular glands [1-3]. Salivary gland enlargement, 
which apperas to be mediated via chronic activa- 
tion of fl-l-adrenergic receptors in the affected 
Abbreviation: QNB, L-quinuclidinyl benzilate. 
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organs [4], is brought about by a combination of 
cellular hyperplasia and hypertrophy [3,5]. Secre- 
tory acini are thus more numerous and the individ- 
ual secretory cells of which they are comprised are 
larger, with increased granule contents [6]. The 
functional features of these glands also appear to 
be altered by chronic isoproterenol treatment. Both 
qualitative and quantitative differences in the pro- 
teins synthesized by submandibular #ands have 
been reported [7]. In addition, both the amounts 
and species of protein in the secretory effluents 
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produced by the parotid [8] and submandibular 
glands [9] are altered by chronic isoproterenol 
treatment, and rates of secretory effluent produc- 
tion elicited by either muscarinic cholinergic [10] 
or a-adrenergic [9] secretagogues are reduced. In 
recent studies on isolated parotid acinar cells from 
isoproterenol-treated rats, Mangos et al. [11] also 
have detected abnormalities in cellular morphol- 
ogy and in the ability of these cells to regulate 
internal cation concentrations and levels of cyclic 
nucleotides. These studies suggest that abnormali- 
ties in the production and composition of parotid 
and submandibular saliva in the isoproterenol- 
treated rat arise from profound alterations in cell- 
ular metabolism in the secretory parenchyma of 
the affected organs. One possible alteration, sug- 
gested by the low flow rates elicited in isopro- 
terenol-treated glands by cholinomimetics, is a re- 
duction in the numbers of cholinergic receptors in 
acinar cells or a decrease in the sensitivity of these 
receptors to activation by acetylcholine and its 
analogues. 
In the studies reported on in the present com- 
munication, I have investigated these possibilities 
by analyzing certain aspects of the binding of the 
muscarinic cholinergic antagonist, L-quinuclidinyl 
[3H]benzilate (QNB) to receptors in homogenates 
prepared from submandibular glands of control 
and chronically isoproterenol-treated rats. Ex- 
orbital lacrimal glands also were included in the 
study as an internal control since, although they 
contain fl-adrenergic receptors which play a minor 
role in secretory effluent production [12], they do 
not undergo enlargement after chronic administra- 
tion of isoproterenol [2]. The results of these ex- 
periments demonstrate that both the average num- 
ber of muscarinic receptors per cell and the affin- 
ity of these receptors for cholinergic agonists are 
decreased in submandibular glands from rats 
treated with isoproterenol for 2-3 weeks. No 
changes in these parameters of [3H]QNB binding 
were seen in lacrimal glands from the same animals. 
Methods 
Animals and treatments. Male Sprague-Dawley 
rats, 4-5-weeks-old, were purchased from Charles 
River Breeding Laboratories, Inc. (Wilmington, 
MA). Upon arrival, rats were divided randomly 
into control and experimental groups of equal size. 
Animals in the experimental group received twice 
daily subcutaneous injections of 0.25 ml of 10 
mg/ml DL-isoproterenol in 0.9% saline for 14-21 
days, a protocol which induces substantial enlarge- 
ment of the salivary glands [11]. Control rats re- 
ceived an identical regimen of saline injections. All 
animals were allowed free access to water and 
laboratory chow throughout this period. Rats re- 
ceived final injections in the evening of the day 
before they were to be used for experimentation 
and were then fasted until use. All rats were killed 
between 7 and 9 a.m. on the days of experiments. 
Reagents. All chemicals used were of reagent 
grade quality. Most were obtained from Fisher 
Scientific Co. (Fair Lawn, N J) and Sigma Chemi- 
cal Co. (St. Louis, MO). L-Quinuclidinyl [3H]ben- 
zilate (33.1 Ci/mmol) was obtained from New 
England Nuclear Corp. (Boston, MA). 
Tissue preparation. Rats were anesthetized on 
the mornings of experiments by intraperitoneal 
injection of 0.25 ml of sodium pentobarbital (50 
mg/ml) and exsanguinated by transsection of the 
dorsal abdominal aorta. The paired submandibu- 
lar and exorbital lacrimal glands were then ex- 
cised, trimmed of connective tissue and weighed. 
Glands were homogenized with a motorized Teflon 
homogenizer in chilled 50 mM sodium phosphate 
buffer (pH 7.4) to a concentration of 10 mg wet 
wt./ml. Homogenates were filtered once through a 
single layer of fine nylon mesh and held on ice. 
[3H]QNB binding assay. The assay used was 
modified from that of Yamamura and Snyder [13]. 
Binding reactions were carried out in 5.0 ml of 
incubation medium consisting of 50 mM sodium 
phosphate buffer (pH 7.4) and varying amounts of 
[3H]QNB, other drugs, and homogenate. Specific 
binding of [3H]QNB to homogenate receptors was 
determined as the difference between binding in 
the absence of atropine (total binding) and in the 
presence of an excess of this competing muscarinic 
antagonist (nonspecific binding). To this end, 
duplicate tubes containing 10 #M atropine sulfate 
in addition to the above were included in each 
assay. 
Binding reactions were initiated by addition of 
0.5 ml of homogenate to tubes containing 4.5 ml 
of temperature-equilibrated incubation medium. 
All incubations in this study were carried out at 
37°C for 120 min, since preliminary experiments 
showed that this length of time was adequate for 
equilibrium binding conditions to be attained at 
25 pM [3H]QNB, the lowest concentration used. 
Incubations were terminated by pouring the sus- 
pensions over Whatman G F / B  glass fiber filters 
mounted in a vacuum filtering apparatus and rins- 
ing each filter three times with 5.0 ml aliquots of 
ice-cold incubation buffer. Rinsed filters were 
placed directly in scintillation vials and extracted 
in a 1 : 10 mixture of Protosol and Omnifluor (New 
England Nuclear). Vials were then counted in a 
Beckman LS-9000 liquid scintillation spectrome- 
ter. 
DNA and protein assay. Protein in gland ho- 
mogenates was estimated by the method of Peter- 
son [14], using bovine serum albumin as a stan- 
dard. DNA was estimated, using calf thymus DNA, 
by the diphenylamine procedure of Croft and 
Lubran [15]. 
Results 
Adaptive response to isoproterenol treatment 
Rats were killed at approx. 50 days of age, after 
2-3 weeks of isoproterenol or saline injections. 
The average weight of isoproterenol-treated rats at 
the time of death was 199 - 10 g. Control animals 
were somewhat heavier at 238---24g. All isopro- 
terenol-treated rats survived the drug regimen with 
few noticeable ill effects other than this small 
depression in weight gain. Conspicuous enlarge- 
ment of the salivary glands was readily seen after 
the first few days of treatment in even a cursory 
external examination of the animals. This enlarge- 
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ment is illustrated by the data in Table I. Sub- 
mandibular glands in isoproterenol-treated rats 
were 3-4-fold heavier than their counterparts in 
control animals. Glandular protein content was 
roughly four times as great, while DNA was in- 
creased 2-fold. These data show that the isopro- 
terenol-induced enlargement of submandibular 
glands is the product of two separate processes, 
hyperplasia within the glandular parenchyma and 
hypertrophy of individual secretory cells, findings 
which confirm those of earlier studies [3,5,10]. No 
differences were noted in gland weights, protein, 
or DNA when lacrimal glands from control and 
isoproterenol-treated rats were compared. 
Characterization of [ 31-1] QNB binding 
Specific binding of [3H]QNB to receptors in 
homogenates of both glands was saturable, as 
shown in Figs. 1 and 2. Nonspecific binding, in 
contrast, was lineraly dependent on concentration 
of [3H]QNB over the range studied, 25-800 pM, 
but did not constitute a major portion of total 
binding at even the highest concentration. The 
specific saturation binding isotherms for both 
glands in both experimental conditions generated 
Scatchard plots consisting of single straightlines 
with correlation coefficients between 0.90 and 1.00 
(Fig. 3). These data indicate that the muscarinic 
receptor in both glands behaves as an homogenous 
class of binding sites with respect to its interaction 
with the tritiated antagonist. Equilibrium dissocia- 
tion constants (Kd) and maximal binding levels 
(Bma x) were determined from these plots and are 
shown in Table II. K d for the [3H]QNB-receptor 
interaction was not altered in either the lacrimal or 
TABLE I 
EFFECT OF DL-ISOPROTERENOL ON RAT LACRIMAL AND SUBMANDIBULAR GLANDS 
Male Sprague-Dawley rats were injected with approx. 25 mg isoproterenol/kg body weight for 14-21 days. Values represent the 
means ± S.E. of determinations from the glands of five animals in each group. 
Gland Wet weight Protein DNA 
(mg) (mg) (mg) 
Lacrimal (control) 77.2 -'- 9.5 9.83 ± 2.15 0.253 ± 0.035 
Lacrimal (isoproterenol) 63.9 ± 7.8 8.25 ± 1.06 0.269-  0.037 
Submandibular(control) 256 ±17  30.8 ± 3.9 1.14 ±0.07 
Submandibular (isoproterenol) 824 ±67  a 126.7 ± 13.6 a 2.22 ±0.11 a 








I I I I 
200 400 600 800 
[ ' . ] ~ e  ipu) 
Fig. 1. Specific binding of [3H]QNB to exorbital lacrimal gland 
homogenate receptors from control (O) and isoproterenol- 
treated (O) glands as a function of medium [3H]QNB con- 
centration. Data points represent the means ± S.E. of five 
experiments for each condition. Incubations were carried out 
for 120 min at 37°C as detailed in the text. 
submandibular glands by chronic isoproterenol 
treatment. The K d in lacrimal glands was some- 
what higher than that in submandibular glands, 
possibly a reflection of the differing plasma mem- 
brane microenvironments in these two organs. Iso- 
proterenol treatment did not alter the maximal 
binding level for [3H]QNB in lacrimal glands, 
either on the basis of protein, DNA,  or total gland 
content. In submandibular glands, however, ad- 
ministration of the fl-adrenergic agonist caused a 
4 L 
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Fig. 2. Specific [3H]QNB binding to receptors in homogenates 
of submandibular glands from control (O) and isoproterenol- 
treated (O) rats expressed as a function of [3H]QNB con- 
centration. Incubation time was 120 min at 37°C. Five experi- 
ments. 
significant ( P < 0 . 0 5 )  depression in [3H]QNB bi- 
nding, expressed relative to either protein or DNA. 
While this decrease is most striking when ex- 
pressed relative to the former (89.4 vs. 27.3 
f m o l / m g  protein), relating specifically bound 
[3H]QNB to D N A  more accurately reflects the 
change in numbers of muscarinic receptors per 
cell. When expressed in this fashion, the decrease 
assumes more modest proportions, 2.22 to 1.52 
f m o l / # g  DNA. This reduction in binding is sig- 
nificant at the 0.05 level. Although average cellular 
receptor populations are depressed in submandib- 
ular glands of isoproterenol-treated rats, the total 
glandular muscarinic receptor complement is in- 
creased somewhat. This increase most probably 
can be attributed to newly synthesized receptors in 
the acinar cells recruited during the hyperplastic 
phase of gland enlargement. 
The possibility that chronic isoproterenol treat- 
ment  might alter the affinity for cholinergic 
agonists of muscarinic receptors in the two glands 
was also explored. Carbachol was added at con- 
centrations from 5 #M to 10 mM to incubation 
media containing 100 pM [3H]QNB and the re- 
suiting competit ion curves were plotted as shown 
in Fig. 4. The  curves  for  con t ro l  and  
isoproterenol-treated lacrimal glands overlapped. 
Hill coefficients for these competition curves were 
0.795 and 0.808, respectively. Inhibition constants 
( K i )  , calculated as in Fields et al. [16], were also 
very similar; 53.6 --- 5.4/~M in controls and 66.6 ± 
7.9 #M in isoproterenol-treated glands ( P  > 0.05). 
These data indicate that chronic administration of 
2( 2( 
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Fig. 3. Scatchard analyses of saturation binding isotherms from 
Figs. 1 and 2. Correlation coefficients (r) for control (O) and 
isoproterenoi-treated (O) lacrimal glands were 0.975 and 0.963, 
respectively. Corresponding values for submandibular glands 
were 0.897 and 0.972. 
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TABLE II 
EFFECT OF DL-ISOPROTERENOL ON [3H]QNB BINDING TO RAT LACRIMAL AND SUBMANDIBULAR GLAND 
MUSCARINIC ACETYLCHOLINE RECEPTORS 
Values represent the means ± S.E. of determinations from the glands of five animals in each group. 
Gland K a Bm.~ 
(pM) 
fmol /mg protein fmol/lag DNA pmol/gland 
Lacrimal (control) 61.3 -4- 5.3 47.4 ± 6.5 1.74-*- 0.24 0.455 ---+ 0.098 
Lacrimal (isoproterenol) 53.2 ± 4.0 58.3 ± 5.3 1.78 ± 0.17 0.467 ± 0.051 
Submandibular (control) 37.8 ± 6.3 89.4 ± 15.7 2.22 -- 0. i 6 2.53 ± 0.24 
Submandibular (isoproterenol) 41.0±4.0 27.3± 2.6 a 1.52±0.10 a 3.38 ±0.29 a 
a Significant difference at 0.05 level, determined by Student's t-test. 
isoproterenol to rats has little, if any, effects on the 
functional properties of muscarinic acetylcholine 
receptors in exorbital lacrimal glands. In contrast, 
isoproterenol treatment caused a substantial shift 
i n t h e  carbachol competition curve with sub- 
mandibular gland homogenates (Fig. 4). The 
calculated K i for control glands was 17.3-  1.4 
/~M, while that for isoproterenol-treated glands 
was 68 .3 -  5.2 #M, a highly significant difference 
(P  < 0.01). Hill coefficients were 0.628 and 0.676, 
respectively. These results suggest a shift toward 
lessened sensitivity to agonists in muscarinic re- 
ceptors of submandibular glands in chronically 
isoproterenol-treated animals. 
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Fig. 4. Inh ib i t ion  of specif ic [ 3 H ] Q N B  binding to receptors in 
homogcnates o f  rat lacrimal an(] submandibular glands from 
control  (@) and isoproterenol-treated ( O )  animals by  carbachoi. 
Med ium [ 3 H ] Q N B  concentrat ion was 100 p M  and incubations 
were carried out at 37°C for 120 rain. Each curve represents the 
average of  three experiments. Standard errors of  means were 







The evidence presented in this paper suggests 
that chronic treatment of rats with DL-isopro- 
terenol, a fl-adrenergic agonist, elicits significant 
qualitative and quantitative differences in the 
muscarinic cholinergic receptors of submandibular 
glands. Receptor properties in exorbital lacrimal 
glands from the same animals, however, remain 
unaffected by the drug treatment. 
Parameters of binding of the muscarinic 
cholinergic antagonist, [3H]QNB, to receptors in 
homogenates from both glands are similar to those 
in other previously examined exocrine organs, in- 
cluding the rat parotid gland [17] and the duck salt 
gland [18]. [3H]QNB binding is saturable,with a 
calculated Ko of less than 100 pM. Binding is also 
competitively inhibited by other muscarinic 
ligands, both antagonists (atropine) and agonists 
(carbachol). Maximal binding levels expressed a 
fmol [3H]QNB/#g DNA can be converted to 
average numbers of receptors per cell, since somatic 
mammalian cells characteristically contain about 
6pg DNA [19]. These conversions give receptor 
numbers of 6290/cell in control lacrimal glands 
and 8020/cell in submandibular glands from con- 
trol rats. These values are in good agreement with 
those of 4900 and 23000 calculated for rat parietal 
cells [20] and parotid acinar cells [21], respectively. 
It is worth noting here that the present values 
represent averages across the glands and thus in- 
clude not only secretory acinar cells but cells in 
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glandular excretory ducts as well as those in con- 
nective tissue and vascular compartments. It is 
thus not possible at present to accurately quanti- 
tate muscarinic receptor populations in specific 
intraglandular cell types, an endeavor that would 
require the application of autoradiographic and /o r  
tissue dispersion and cell separation techniques. 
In the submandibular glands, a decrease in 
cellular muscarinic receptors of approx. 30% was 
observed following 2-3 weeks of chronic isopro- 
terenol administration. Although this represents a 
significant depression in the calculated average 
number of receptors per cell (8020-5490), it is 
again not possible to say with certainty whether 
this represents a moderate generalized reduction 
or a more dramatic decrease in a particular cell 
type. Indirect evidence, however, suggests that ac- 
inar cells in particular may be those most affected. 
Studies with dispersed rat submandibular acini 
have demonstrated their responsiveness to both 
muscarinic cholinergic and /3-adrenergic stimuli 
[22-24]. In addition, the hypertrophic and hyper- 
plastic responses seen in submandibular glands to 
chronic isoproterenol administration primarily in- 
volve secretory acini. Striated and granular duct 
cells are not markedly enlarged [10]. It thus is 
reasonable to assume that the reduction in 
muscarinic receptors observed represents a reduc- 
tion in the receptor complement of acinar cells, a 
decrease that may actually exceed the average 
reduction measured. 
The other significant alteration in submandibu- 
lar muscarinic acetylcholine receptors induced by 
chronic isoproterenol treatment was a decrease in 
the affinity of the receptor for carbachol. The 
competition binding curves for this agonist from 
both control and isoproterenol-treated glands give 
Hill coefficients that are lower than expected from 
a simple mass action competition. Birdsall et al. 
[25], Schimerlik and Searles [26] and others have 
recently demonstrated that this discrepancy can be 
explained if muscarinic receptors contain two 
binding sites with identical affinities for 
antagonists but which differ in their affinities for 
agonists. Thus, muscarinic receptors in the sub- 
mandibular gland appear to be homogenous with 
respect to their affinity for antagonists (Fig. 3) and 
heterogenous with respect to agonist affinities 
(Fig. 4). Chronic isoproterenol administration de- 
creased the ability of carbachol to inhibit [3 H]QNB 
binding to submandibular gland homogenates by 
approx. 4-fold, as judged by the shift in K~ from 
17.3 to 68.3 ~M. Accompanying this alteration in 
binding affinity was a small increase in the Hill 
coefficient from 0.63 to 0.68. These data are strik- 
ingly similar to those obtained in embryonic chick 
heart [27], where in ovo treatment with carbachol 
decreased the ICs0 for carbachol inhibition of 
[3H]QNB binding from 8 to 32 ~M (4-fold) and 
increased the Hill coefficient from 0.52 to 0.65. In 
this study, the increase in Hill coefficient was 
clearly shown to result from a decrease in the 
heterogeny of the receptor population brought 
about by a preferential reduction in the proportion 
of high affinity agonist binding sites, an alteration 
that decreases the average affinity of the receptor 
population for agonists as well. The close corre- 
spondence of data obtained in the present study 
suggests that similar alterations may take place in 
the muscarinic receptor population of submandib- 
ular glands from rats undergoing chronic isopro- 
terenol treatment. 
Reduction of muscarinic receptors by chronic 
receptor activation has been observed in a number 
of biological systems, including embryonic chick 
heart [27], cultured neuroblastoma cells [28], and 
intact rat brain [29] and pancreas [30]. The fact 
that depression of muscarinic receptors in secre- 
tory epithelia can also be elicited by chronic /3- 
adrenergic stimulation appears to be a novel ob- 
servation. Little is known about the way in which 
/3-adrenergic and muscarinic cholinergic stimulus- 
response coupling systems in epithelia feedback on 
each other at the subcellular level, although Burke 
and Barka [31] recently demonstrated that chronic 
isoproterenol treatment increases cyclic AMP levels 
in intact salivary glands. This finding is confirmed 
by the studies of Mangos et al. [11] on dispersed 
parotid acinar cells. In this latter study, a recipro- 
cal decrease in intracellular cyclic GMP levels was 
also observed. Whether these changes are directly 
involved in modulation of muscarinic acetylcho- 
line receptor numbers and sensitivity to agonists 
remains to be elucidated. The profound stimula- 
tory effects of isoproterenol administration on 
DNA and protein synthesis in the submandibular 
gland raise the possibility that muscarinic receptor 
synthesis might be affected at the transcriptional 
or translational level. 
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An interesting feature in the present study was 
the complete absence of effects of isoproterenol 
administration on the exorbital lacrimal glands. 
Acinar cells in these glands contain fl-adrenergic 
receptors [12] although, in contrast to submandib- 
ular glands, they apparently play only a minor role 
in secretory effluent production. Why isopro- 
terenol administration does not induce cell divi- 
sion or hypertrophy, or alter the properties of 
muscarinic receptors, therefore must not be the 
absence of receptors for the agonist. More subtle 
features of receptor-effector coupling are likely 
involved. 
The decrease seen in muscarinic receptors and 
in their agonist sensitivity in submandibular glands 
of isoproterenol-treated rats may have important 
functional significance with respect to secretory 
effluent production. When compared with control 
animals, salivary production by treated glands 
shows substantial differences. Protein concentra- 
tion in saliva is elevated while the flow rate is 
markedly reduced [9,10]. In addition, there are 
qualitative differences in the species of proteins 
secreted [9]. The difference in flow rate could 
clearly result from a decreased cholinergic 
responsiveness without there being marked changes 
in the ionic composition of the primary effluent 
produced by secretory acini. The combination of 
low flow rates and increased protein concentration 
in submandibular saliva may increase the viscosity 
of the secreted fluid and thus predispose the treated 
animals to glandular excretory duct obstructions 
and pathologic infections. Isoproterenol-treated 
rats, for instance, have a greater incidence of den- 
tal caries than control animals [32]. Interestingly, 
pathological symptoms of this nature have also 
been reported in patients with cystic fibrosis, a 
disease for which the chronically isoproterenolized 
rat has been suggested as an animal model [I 1]. It 
will be of great interest in the future to determine 
whether fundamental alterations in muscarinic 
receptors in the salivary glands of affected individ- 
uals contribute to the exocrinopathy of this disease 
as they appear to contribute to abnormal sub- 
mandibular gland function in the isoproterenol- 
treated rat. 
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